US BROKER MOVES: KDP upgraded at Morgan Stanley; MRK downgraded at RBC and UBS

• Keurig Dr Pepper (KDP) initiated Overweight w/ USD 38.00 PT at Morgan Stanley
• Progressive (PGR) upgraded from Market Perform to Outperform w/ USD 250.00 PT at Keefe, Bruyette & Woods
• Etsy (ETSY) upgraded from Neutral to Buy w/ USD 105.00 PT (prev. USD 88.00) at BofA Securities
• EPR Properties (EPR) upgraded from Sector Weight to Overweight w/ USD 70.00 PT at KeyBanc
• Crown Castle (CCI) upgraded from Equalweight to Overweight w/ USD 84.00 PT (prev. USD 92.00) at Barclays
• American Tower (AMT) upgraded from Equalweight to Overweight w/ USD 198.00 PT (prev. USD 195.00) at Barclays
• Analog Devices (ADI) upgraded from Neutral to Buy w/ USD 425.00 PT at Seaport Global Securities
• Ternium (TX) upgraded from Hold to Buy w/ USD 22.00 PT at Deutsche Bank
• Pony AI (PONY) upgraded from Neutral to Outperform at BNP Paribas Exane

• Western Midstream (WHD) downgraded from Buy to Neutral w/ USD 75.00 PT (prev. USD 67.00) at Citi
• TJX Companies (TJX) downgraded from Buy to Neutral at Citi
• TJX Companies (TJX) downgraded from Buy to Accumulate w/ USD 155.00 PT at Gordon Haskett
• Nvni Group (NVNI) downgraded from Buy to Hold at Maxim Group
• Merck (MRK) downgraded from Outperform to Sector Perform w/ USD 150.00 PT (prev. USD 142.00) at RBC Capital
• Merck (MRK) downgraded from Buy to Neutral w/ USD 150.00 PT at UBS
• Liberty Latin America (LILA) downgraded from Equalweight to Underweight w/ USD 7.00 PT at Morgan Stanley
• Gerdau (GGB) downgraded from Buy to Neutral w/ USD 5.10 PT at BofA Securities
• Equinor (EQNR) downgraded from Buy to Neutral w/ USD 46.00 PT at Gerdes Energy Research
• Coty (COTY) downgraded from Outperform to Sector Perform w/ USD 3.00 PT at RBC Capital
• Allstate (ALL) downgraded from Market Perform to Underperform w/ USD 250.00 PT at Keefe, Bruyette & Woods

• UMB Financial (UMBF) initiated Overweight w/ USD 180.00 PT at JPMorgan
• Surrozen (SRZN) initiated Outperform at William Blair
• Sphere Entertainment (SPHR) initiated Overweight w/ USD 185.00 PT at Piper Sandler
• Quince Therapeutics (QNCX) initiated Buy w/ USD 68.00 PT at Craig-Hallum
• ProQR Therapeutics (PRQR) initiated Buy w/ USD 8.00 PT at BofA Securities
• Progyny (PGNY) initiated Overweight w/ USD 37.00 PT at Wells Fargo
• Madison Square Garden Entertainment (MSGE) initiated Neutral w/ USD 86.00 PT at Piper Sandler
• Monolithic Power Systems (MPWR) initiated Buy w/ USD 2,013.00 PT at Arete
• Milestone Pharmaceuticals (MIST) initiated Overweight w/ USD 3.00 PT at Cantor Fitzgerald
• Lifeway Foods (LWAY) initiated Buy w/ USD 32.00 PT at BTIG
• Keurig Dr Pepper (KDP) initiated Overweight w/ USD 38.00 PT at Morgan Stanley
• Incyte (INCY) initiated Buy w/ USD 152.00 PT at Canaccord
• Freenome (FRNM) initiated Buy w/ USD 21.00 PT at Guggenheim
• CalciMedica (CALC) initiated Buy w/ USD 9.00 PT at Guggenheim
• Bitdeer Technologies (BTDR) initiated Overweight w/ USD 15.00 PT at Barclays
• Ardagh Metal Packaging (AMBP) initiated Hold w/ USD 5.20 PT at Deutsche Bank
• Alpha Cognition (ACOG) initiated Buy w/ USD 21.00 PT at B. Riley

Daily broker roundups of this size rarely move indices; what professionals scan for is clustering, where several houses act on the same name or the same sector in one session. The clearest cluster here is Merck, downgraded at both RBC and UBS, and paired downgrades from separate houses have historically carried more signal than a single call because they suggest a shared read on the underlying fundamentals rather than one analyst's view. The Barclays pairing of Crown Castle and American Tower on the same day points the other way, a house-level sector call on tower REITs, a pattern where the initiating bank is typically repositioning a whole coverage group and peer names tend to follow in subsequent weeks. Note also that several of these moves pair a rating cut with a price target raised or left above prior levels, a combination that usually signals relative-value reshuffling within coverage rather than a deterioration in the story, and the market reaction in such cases has tended to be muted. Single-name initiations at smaller shops, particularly in micro-cap biotech, have historically produced the sharpest one-day moves in the underlying, since float and existing coverage are thin. Worth watching is whether the Merck calls are followed by peers over coming sessions and whether the tower upgrade is a one-house view or the start of a broader sector rerating.